Synmosa Biopharma (4114) — Cash Flow Quality Index
Synmosa Biopharma (4114) has a Cash Flow Quality Index of 0.98x as of December 2025. Operating cash flow of NT$185.72 Million is below net income of NT$189.22 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore 4114 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Synmosa Biopharma Cash Flow Quality Index (2015–2025)
Historical Cash Flow Quality Index for Synmosa Biopharma across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 4114 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Synmosa Biopharma (2015–2025)
Year-by-year earnings quality comparison for Synmosa Biopharma. For live market cap and the full company financial profile, see Synmosa Biopharma market capitalisation.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.50x | NT$411.57 Million | NT$821.85 Million | ▼ -56.1% |
| 2024 | 1.14x | NT$780.62 Million | NT$684.68 Million | ▲ +24.2% |
| 2023 | 0.92x | NT$511.93 Million | NT$557.82 Million | ▲ +16.4% |
| 2022 | 0.79x | NT$630.25 Million | NT$799.09 Million | ▼ -46.1% |
| 2021 | 1.46x | NT$444.29 Million | NT$303.86 Million | ▲ +266.8% |
| 2020 | 0.40x | NT$254.40 Million | NT$638.11 Million | ▲ +141.8% |
| 2019 | -0.95x | NT$-44.88 Million | NT$47.09 Million | ▼ -2667.5% |
| 2018 | 0.04x | NT$16.00 Million | NT$430.90 Million | ▲ +103.4% |
| 2017 | -1.11x | NT$-5.19 Million | NT$4.69 Million | ▼ -178.1% |
| 2016 | 1.42x | NT$236.48 Million | NT$166.65 Million | ▲ +89.6% |
| 2015 | 0.75x | NT$23.60 Million | NT$31.54 Million | — |